Form 4 for RNAC Cartesian Therapeutics, Inc.
Accepted 2024-11-18 00:00:00 ET · period of report 2024-11-14 · accession 0001453687-24-000128 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-11-18 | 2024-11-14+ | RNAC | Jewell Christopher M | CSO | M - OptEx | $3.23 | +52.1K | 42.0K | New | +$168.3K |
| DM | 2024-11-18 | 2024-11-14+ | RNAC | Jewell Christopher M | CSO | S - Sale+OE | $16.79 | -52.1K | 25.9K | -67% | -$875.0K |
| DM | 2024-11-18 | 2024-11-14+ | RNAC | Jewell Christopher M | CSO | M - OptEx | — | -52.1K | 106.5K | -33% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-14 | M | A | 36,050 | $3.23 | 61,990 | D | — | — | |
| 2 | Common | Common Stock | 2024-11-14 | S | D | 18,550 | $16.34 | 43,440 | D | — | — | (F1) The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $16.00 to $16.89. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2024-11-15 | S | D | 16,065 | $17.06 | 25,940 | D | — | — | (F3) The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $17.00 to $17.24. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2024-11-15 | M | A | 16,065 | $3.23 | 42,005 | D | — | — | |
| 5 | Common | Common Stock | 2024-11-14 | S | D | 17,500 | $17.02 | 25,940 | D | — | — | (F2) The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $17.00 to $17.18. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 6 | Derivative | Stock Option (Right to Buy) | 2024-11-15 | M | D | 16,065 | — | 90,432 | D | $3.23 · — to 2033-01-15 | 16,065 Common Stock | (F5) On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock. (F4) The option is currently exercisable for 123,235 shares of Common Stock and becomes exercisable for an additional 2,969 shares of Common Stock each month until it is fully exercisable on June 16, 2025. |
| 7 | Derivative | Stock Option (Right to Buy) | 2024-11-14 | M | D | 36,050 | — | 106,497 | D | $3.23 · — to 2033-01-15 | 36,050 Common Stock | (F5) On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock. (F4) The option is currently exercisable for 123,235 shares of Common Stock and becomes exercisable for an additional 2,969 shares of Common Stock each month until it is fully exercisable on June 16, 2025. |